The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Comparing progression-free survival in the ASTRIS and SANOVO trials
Qing Zhou, MD, PhD, Guangdong Lung Cancer Institute, Guangzhou, China, talks about the real world ASTRIS trial (NCT02474355), investigating osimertinib in patients with EGFR T790M-mutated non-small cell lung cancer (NSCLC). Dr Zhou discusses the results from the ASTRIS trial and compares the progression-free survival (PFS) rates to the Phase III SANOVO trial (NCT05009836). She discusses how both studies yielded similar PFS rates (11 months in ASTRIS and 10 months in SANOVO), which suggests that in both a clinical and real world setting, osimertinib is able to achieve consistent results in the EGFR T790M population. Dr Zhou hopes that in the future, other important endpoints from the ASTRIS trial can be analyzed. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
